MY201954A - Pharmaceutical composition comprising nebivolol with improved dissolution rate - Google Patents
Pharmaceutical composition comprising nebivolol with improved dissolution rateInfo
- Publication number
- MY201954A MY201954A MYPI2018702352A MYPI2018702352A MY201954A MY 201954 A MY201954 A MY 201954A MY PI2018702352 A MYPI2018702352 A MY PI2018702352A MY PI2018702352 A MYPI2018702352 A MY PI2018702352A MY 201954 A MY201954 A MY 201954A
- Authority
- MY
- Malaysia
- Prior art keywords
- nebivolol
- pharmaceutical composition
- dissolution rate
- preparation
- pharmaceutically acceptable
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title abstract 6
- 229960000619 nebivolol Drugs 0.000 title abstract 6
- 238000004090 dissolution Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960004796 rosuvastatin calcium Drugs 0.000 abstract 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160002626 | 2016-01-08 | ||
| KR1020160171842A KR102203229B1 (ko) | 2016-01-08 | 2016-12-15 | 용출률이 개선된 네비보롤을 포함하는 약학적 조성물 |
| PCT/KR2016/014771 WO2017119629A1 (ko) | 2016-01-08 | 2016-12-16 | 용출률이 개선된 네비보롤을 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY201954A true MY201954A (en) | 2024-03-25 |
Family
ID=59430720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018702352A MY201954A (en) | 2016-01-08 | 2016-12-16 | Pharmaceutical composition comprising nebivolol with improved dissolution rate |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR102203229B1 (zh) |
| CN (1) | CN108463250B (zh) |
| AU (1) | AU2016385282B2 (zh) |
| CA (1) | CA3010857C (zh) |
| MX (1) | MX2018008443A (zh) |
| MY (1) | MY201954A (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024055984A1 (zh) * | 2022-09-14 | 2024-03-21 | 上海云晟研新生物科技有限公司 | 奈必洛尔与氨氯地平组合物、其制备方法及应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101022791B (zh) * | 2004-06-04 | 2011-11-16 | 麦兰实验室公司 | 含奈必洛尔的组合物 |
| RU2378272C2 (ru) * | 2004-07-30 | 2010-01-10 | Торрент Фармасьютикалз Лимитед | Небиволол и его фармацевтически приемлемые соли, способ их получения и фармацевтические композиции небиволола |
| JP2008528626A (ja) * | 2005-01-31 | 2008-07-31 | マイラン ラボラトリーズ インク． | ヒドロキシル化されたネビボロールを含む薬学的組成物 |
| EP1982711A1 (en) * | 2005-05-31 | 2008-10-22 | Mylan Laboratories, Inc | Compositions comprsing nebivolol |
| CN100508971C (zh) * | 2007-03-30 | 2009-07-08 | 北京福瑞康正医药技术研究所 | 一种具有血管扩张作用和β1受体阻滞作用的药物组合物 |
| FR2920311B1 (fr) * | 2007-08-31 | 2010-06-18 | Galenix Innovations | Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation |
| CN101361720A (zh) * | 2008-10-08 | 2009-02-11 | 刘全胜 | 盐酸奈必洛尔口腔崩解片及其制备方法 |
| US20100143486A1 (en) * | 2008-12-10 | 2010-06-10 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| WO2011028016A2 (ko) * | 2009-09-04 | 2011-03-10 | 한올바이오파마주식회사 | 베타 아드레날린 차단제와 안지오텐신-2 수용체 길항제를 포함하는 약제학적제제 |
| GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| KR20110117758A (ko) * | 2010-04-22 | 2011-10-28 | 한올바이오파마주식회사 | 베타 아드레날린 차단제 및 ＨＭＧ－ＣｏＡ 환원 효소 억제제를 함유하는 약제학적 제제 |
| KR20110130872A (ko) * | 2010-05-28 | 2011-12-06 | 현대약품 주식회사 | 결정형 염산 네비볼롤을 포함하는 약학 조성물 및 제조방법 |
| CN102304103A (zh) * | 2011-06-03 | 2012-01-04 | 郑州泰基鸿诺药物科技有限公司 | 一种非诺贝特酸盐、制备方法、药物组合物及应用 |
| US20140057954A1 (en) * | 2012-08-22 | 2014-02-27 | Forest Laboratories Holdings Ltd. | Chemical composition |
| CN103860492A (zh) * | 2012-12-18 | 2014-06-18 | 重庆福安药业集团庆余堂制药有限公司 | 盐酸奈必洛尔的口服固体药物组合物及其制备方法 |
| CN104688708B (zh) * | 2013-12-06 | 2017-06-23 | 北京万生药业有限责任公司 | 一种阿托伐他汀钙制剂的制备方法 |
| CN103655454A (zh) * | 2013-12-27 | 2014-03-26 | 辽宁亿灵科创生物医药科技有限公司 | 一种兰索拉唑药物组合物 |
| CN103816124B (zh) * | 2014-03-19 | 2016-08-17 | 国药集团致君（深圳）制药有限公司 | 一种埃索美拉唑含药微丸组合物及其制备方法 |
-
2016
- 2016-12-15 KR KR1020160171842A patent/KR102203229B1/ko active IP Right Grant
- 2016-12-16 MX MX2018008443A patent/MX2018008443A/es unknown
- 2016-12-16 AU AU2016385282A patent/AU2016385282B2/en active Active
- 2016-12-16 CA CA3010857A patent/CA3010857C/en active Active
- 2016-12-16 CN CN201680078111.1A patent/CN108463250B/zh active Active
- 2016-12-16 MY MYPI2018702352A patent/MY201954A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3010857A1 (en) | 2017-07-13 |
| KR102203229B1 (ko) | 2021-01-14 |
| CN108463250B (zh) | 2021-07-30 |
| CA3010857C (en) | 2020-09-15 |
| CN108463250A (zh) | 2018-08-28 |
| AU2016385282A1 (en) | 2018-08-23 |
| MX2018008443A (es) | 2019-05-30 |
| AU2016385282B2 (en) | 2019-11-21 |
| KR20170083484A (ko) | 2017-07-18 |
| AU2016385282A2 (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502092A1 (en) | Topical pharmaceutical compositions | |
| PH12017501421A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MX2019012884A (es) | Terapia de combinacion. | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| MX2020007554A (es) | Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio. | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| JOP20180071B1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| TN2015000386A1 (en) | Formulations of organic compounds | |
| EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
| MX2015017879A (es) | Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa. | |
| MX2021004551A (es) | Composicion farmaceutica para el tratamiento de la anemia aplasica. | |
| MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
| MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| MY201954A (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate |